Skip to Content

Nova Mentis Life Science Corp NMLSF

Morningstar Rating
$0.01 0.00 (9.24%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NMLSF is trading at a 36% discount.
Price
$0.01
Fair Value
$9.94
Uncertainty
Extreme
1-Star Price
$4.81
5-Star Price
$8.62
Economic Moat
Yqcwyyh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NMLSF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.06
Bid/Ask
$0.01 / $0.02
Market Cap
$1.91 Mil
Volume/Avg
26,792 / 76,835

Key Statistics

Price/Earnings (Normalized)
Price/Sales
90.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees

Valuation

Metric
NMLSF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
90.00
Price/Cash Flow
Price/Earnings
NMLSF

Financial Strength

Metric
NMLSF
Quick Ratio
0.05
Current Ratio
0.06
Interest Coverage
Quick Ratio
NMLSF

Profitability

Metric
NMLSF
Return on Assets (Normalized)
−241.12%
Return on Equity (Normalized)
−1,608.35%
Return on Invested Capital (Normalized)
−1,768.11%
Return on Assets
NMLSF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXfhvj$541.7 Bil
VRTX
Vertex Pharmaceuticals IncDcxssh$111.3 Bil
REGN
Regeneron Pharmaceuticals IncMsvxvs$109.0 Bil
MRNA
Moderna IncMrszt$36.8 Bil
ARGX
argenx SE ADRKgcb$24.3 Bil
BNTX
BioNTech SE ADRZdwl$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncMjlbrb$20.0 Bil
BMRN
Biomarin Pharmaceutical IncMsqpb$17.1 Bil
RPRX
Royalty Pharma PLC Class AYjxpth$14.0 Bil
INCY
Incyte CorpQxgyms$13.7 Bil

Sponsor Center